A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q(10) Therapy in Hypertensive Patients With the Metabolic Syndrome

作者：Young Joanna M^*; Florkowski Christopher M; Molyneux Sarah L; McEwan Roberta G; Frampton Christopher M; Nicholls M Gary; Scott Russell S; George Peter M

来源：American Journal of Hypertension, 2012, 25(2): 261-270.

DOI：10.1038/ajh.2011.209

• ambulatory blood pressure monitoring
• arterial pressure
• blood pressure
• clinical trial
• coenzyme Q10
• hypertension
• metabolic syndrome

BACKGROUND %26lt;br%26gt;Our aim was to examine the effects of adjunctive coenzyme Q(10) therapy on 24-h ambulatory blood pressure (BP) in subjects with the metabolic syndrome and inadequate BP control. %26lt;br%26gt;METHODS %26lt;br%26gt;In a randomized, double-blind, placebo-controlled 12-week crossover trial, coenzyme Q(10) (100 mg twice daily) or placebo was administrated to 30 subjects with the metabolic syndrome, and inadequate BP control (an average clinic BP of %26gt;= 140 systolic mm Hg or %26gt;= 130 mm Hg for patients with type 2 diabetes) while taking an unchanged, conventional antihypertensive regimen. Clinic and 24-h ambulatory BP were assessed pre- and post-treatment phases. The primary outcomes were the changes in 24-h systolic and diastolic BP during adjunctive therapy with coenzyme Q(10) vs. placebo and prespecified secondary outcomes included changes in BP loads. %26lt;br%26gt;RESULTS %26lt;br%26gt;Compared with placebo, treatment with coenzyme Q(10) was not associated with statistically significant reductions in systolic (P = 0.60) or diastolic 24-h ambulatory BP (P = 0.12) or heart rate (P = 0.10), although daytime diastolic BP loads, were significantly lower during coenzyme Q(10) administration with thresholds set at %26gt;90 mm Hg (P = 0.007) and 85 mm Hg (P = 0.03). Coenzyme Q(10) was well tolerated and was not associated with any clinically relevant changes in safety parameters. %26lt;br%26gt;CONCLUSIONS %26lt;br%26gt;Although it is possible that coenzyme Q(10) may improve BP control under some circumstances, any effects are likely to be smaller than reported in previous meta-analyses. Furthermore, our data suggest that coenzyme Q(10) is not currently indicated as adjunctive antihypertensive treatment for patients with the metabolic syndrome whose BP control is inadequate, despite regular antihypertensive therapy.

• 出版日期2012-2